Breast Cancer Research and Treatment

, Volume 119, Issue 1, pp 87–93

CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers

  • Sarai Palanca Suela
  • Eva Esteban Cardeñosa
  • Eva Barragán González
  • Inmaculada de Juan Jiménez
  • Isabel Chirivella González
  • Ángel Segura Huerta
  • Carmen Guillén Ponce
  • Eduardo Martínez de Dueñas
  • Joaquín Montalar Salcedo
  • Victoria Castel Sánchez
  • Pascual Bolufer Gilabert
  • On Behalf of the Group for Assessment of Hereditary Cancer of Valencia Community
Preclinical study

DOI: 10.1007/s10549-009-0316-2

Cite this article as:
Palanca Suela, S., Esteban Cardeñosa, E., Barragán González, E. et al. Breast Cancer Res Treat (2010) 119: 87. doi:10.1007/s10549-009-0316-2

Abstract

The polymorphic genetic differences among individuals may modify the high risk for breast cancer (BC) and/or ovarian cancer (OC) susceptibility conferred by BRCA1 and BRCA2 mutations. In the present study we investigate the relevance of RAD51 −135C > G, TP53 R72P, NQO1*2 and CASP8 D302H polymorphisms as potential modifiers of BC and/or OC susceptibility conferred by these mutations. The study group encompasses 390 BRCA1/BRCA2 mutation carriers (182 affected with BC and/or OC and 208 unaffected) of 131 unrelated families studied in the Program of Genetic Counselling on Cancer of Valencia Community. The polymorphisms were detected in genomic DNA by ASRA method or real time PCR using fluorescently labeled probes. We found similar incidence of RAD51 −135C > G, TP53 R72P and NQO1*2 polymorphisms among affected and unaffected individuals considering BRCA1/BRCA2 mutations together and separately. However, the CASP8 D302H polymorphism was strongly associated with the absence of BC [OR = 3.41 (95% CI 1.33–8.78, P = 0.01)]. In fact, in the females with CASP8 D302H polymorphism the BC appeared at a median age of 58 in opposition to the 47 years observed for the wild type subjects (P = 0.03). Furthermore, the CASP8 D302H positive females showed a 50% probability of being free of BC by the age of 78 versus the 2% of the CASP8 negative ones. Our results support that the presence of the CASP8 D302H polymorphism diminishes the high risk of BC conferred by BRCA1 and BRCA2 mutations, making possible that some of the carriers could escape from suffering BC along their life span.

Keywords

BRCA1/BRCA2 mutation carriers Breast cancer CASP8 D302H polymorphism 

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Sarai Palanca Suela
    • 1
    • 6
  • Eva Esteban Cardeñosa
    • 1
    • 6
  • Eva Barragán González
    • 1
    • 6
  • Inmaculada de Juan Jiménez
    • 1
    • 6
  • Isabel Chirivella González
    • 2
  • Ángel Segura Huerta
    • 3
    • 6
  • Carmen Guillén Ponce
    • 4
  • Eduardo Martínez de Dueñas
    • 5
  • Joaquín Montalar Salcedo
    • 6
  • Victoria Castel Sánchez
    • 6
  • Pascual Bolufer Gilabert
    • 1
    • 6
    • 7
  • On Behalf of the Group for Assessment of Hereditary Cancer of Valencia Community
  1. 1.Molecular Biology Laboratory (Service of Analytical Chemistry)Hospital Universitario La FeValenciaSpain
  2. 2.Unit of Genetic Counselling in CancerHospital Clínico UniversitarioValenciaSpain
  3. 3.Unit of Genetic Counselling in CancerHospital Universitario La FeValenciaSpain
  4. 4.Unit of Genetic Counselling in CancerHospital General de ElcheAlicanteSpain
  5. 5.Unit of Genetic Counselling in CancerConsorcio Hospital ProvincialCastellónSpain
  6. 6.Group of Clinical and Translational Research in CancerHospital Universitario La FeValenciaSpain
  7. 7.Laboratorio de Biología Molecular, Escuela de Enfermería 7ª plantaHospital Universitario La FeValenciaSpain

Personalised recommendations